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61. Introduction
The availability and integrated use of advanced genome analysis
platforms in recent years by consortia such as the Human Genome
Project, Functional Annotation of the Mammalian genome project
(FANTOM), and the Encyclopedia of DNA elements (ENCODE) project,
have revealed that only a very small proportion of the actively
transcribed human genome corresponds to protein-coding genesC, Highly upregulated in liver
on-coding RNA; lincRNA, Long
iated in lung adenocarcinoma
NAs; NATs, Natural antisense
ring RNAs.
lo Road, Jacksonville, FL 32224,
. This is an open access article under(Dingemans et al., 2014; Fatemi, Velmeshev, & Faghihi, 2014; Z. Zhang
et al., 2014). The recognition and identiﬁcation of transcribed RNAs
such as the microRNAs that do not encode for proteins but yet have
speciﬁc biological functions have prompted a re-evaluation of the
central dogma and emphasize a versatile role of RNA beyond that of a
transitional role in translation of DNA to protein. The large numbers of
pervasive non-coding RNA transcripts allows us to presume that many
functionally active and biologically relevant non-coding RNA (ncRNA)
remain to be identiﬁed. Considering their ubiquitous presence and di-
versity, these non-coding RNA could be major contributors to normal
cellular physiological processes.
1.1. Classiﬁcation of RNA genes
NcRNAs can be arbitrarily classiﬁed into two groups based on the
length of their transcripts. Small RNAs, with less than 200 nucleotides,
include several distinct types of RNAs such as microRNAs, smallthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ing RNAs. Long RNAs, greater than 200 nucleotides, include long
intergenic non-coding RNAs (lincRNAs), natural antisense transcripts
(NATs), transcribed ultra-conserved regions (T-UCRs), long enhancer
ncRNAs, non-coding repeat sequences, and pseudogenes. In contrast
to some types of small ncRNAs such as microRNAs (miRNAs) and
small interfering RNAs (siRNAs), the mechanism and functions of long
ncRNAs (lncRNAs) are very poorly understood (Dingemans et al.,
2014; Kimura et al., 2015; Y. Yang, H. Li et al., 2013).
The lncRNAs are a highly abundant and heterogeneous group, in part
reﬂecting their enormous diversity and structural complexity. Pointers
to a functional biological role include the recognition of tissue-speciﬁc
expression patterns, emerging literature showing functional relevance
in complex physiological and pathological processes, and evidence of
their involvement in several human diseases. In contrast to the protein
coding genes, the number of lncRNAs has increased tremendously along
the evolutionary process and reﬂects the complexity of the organism.
(Necsulea et al., 2014). Despite this, an effective and useful method to
categorize this large and heterogeneous group is lacking. A descriptive
classiﬁcation is based on genomic proximity to protein-coding genes.
Depending on genomic location, they can be divided broadly into sever-
al categories (Fig. 1): 1. Intronic lncRNAs are located within an intron of
a coding gene; 2. intergenic lncRNAs (lincRNAs) are present between
two protein-coding genes; 3. bidirectional lncRNAs are expressed with-
in the vicinity (within 1 kb) of a coding transcript of the opposite strand;
4. enhancer lncRNAs (e-lncRNAs) are present in the enhancer regions
close to the promoter; 5. sense: or 6. antisense lncRNAs are those that
overlap with one or more introns and exons of a different transcript
on the same or opposite strand, respectively (Devaux et al., 2015;
Hirose et al., 2014; H. Takahashi & Carninci, 2014). Non-coding repeats
are another important class of lncRNAs that can have biological
functions.
While a location-based classiﬁcationmay be useful for their recogni-
tion and annotation, an accurate classiﬁcation of lncRNAs with respect
to their biological role or biological activity is lacking.
Efforts to develop lncRNA databases have used systematic identiﬁca-
tion and annotation of lncRNAs within the human genome. The cDNA
clone analysis within the FANTOM project led to the identiﬁcation of
over 23,000 lncRNAs (Carninci et al., 2005), while the GENCODE-
ENCODE project identiﬁed approximately 24,000 lncRNA producing
loci (Derrien et al., 2012). An analysis of a compendium of 7256 RNA-Fig. 1. Non-coding RNA. Non-coding RNA comprise a much larger portion of the human
genome than protein-coding RNA, which comprise b3% of the genome. Non-coding
RNAs are arbitrarily classiﬁed into short and long non-coding RNA based on transcript
size. LncRNA can be designated as Intergenic, Intronic, Enhancer, Sense, Antisense, or
Bidirectional based on their genomic location relative to that of nearby protein-coding
genes.seq libraries from tumors, normal tissues, and cell lines and comprehen-
sively delineated genome-wide lncRNA expression reported the identi-
ﬁcation of 58,648 lncRNA genes (Iyer et al., 2015).
1.2. Mechanisms of action
As may be expected from their structural diversity, a wide range of
functions have been described for lncRNAs. These include gene
transcription, epigenomic regulation, translation of protein-coding
genes, RNA turnover, chromatin organization, and genome defense
(Ferraiuolo et al., 2010). Notably, most of the functions described to
date involve regulation of gene expression, both of protein-coding
genes or other non-coding RNAs, through a multitude of mechanisms
as outlined in Table 1 and Fig. 2. LncRNAs differ from small RNAs in
both complexity and length. The structural complexity of lncRNAs offers
multiple possibilities for interactions with DNA, RNA, and/or proteins
that depend on the secondary and tertiary structures. Likewise, the
length of lncRNAs enables the formation of multi-component com-
plexes such as those involved in epigenetic regulation of transcription.
LncRNAs may be transcribed from DNA in several orientations and can
interact with genomic DNA elements, as well as with proteins in multi-
ple conﬁgurations.
While the majority of lncRNA are present within the cytoplasm,
some lncRNAs are primarily conﬁned within the nucleus (Z. Zhang
et al., 2014). Trans-acting nuclear lncRNAs can act in a tissue-speciﬁc
manner in conjunction with chromatin modiﬁers such as histone-
modifying complexes and DNA methyltransferases, to epigenetically
regulate or to modulate transcription (Tao et al., 2013). However, the
mechanism by which these lncRNAs can recognize speciﬁc genomic
loci is not well understood. It is hypothesized that interactions with
genomic regions may be dictated by secondary or tertiary structural el-
ements. Efforts to deﬁne and categorize RNA structural modules may
enable systematic approaches to evaluate this hypothesis in the future.
Some lncRNAshave been shown tomaintain the nuclear architecture by
scaffolding the assembly of DNA–RNA-protein interface at speciﬁc
locations. In contrast, cis-acting lncRNAs may be able to regulate gene
expression in a locus and allele-speciﬁc manner because of their geno-
mic proximity to their targets. Cis-acting lncRNAs have been implicated
in genomic imprinting, dosage compensation, and enhancer functions
(Chen, Xu, & Liu, 2013; Xu et al., 2013). In such cases, modulation of
neighboring gene expression can occur via direct binding or through
the recruitment of chromatin-binding proteins that can modify the
chromatin structure in the vicinity. While most of the well-studied
lncRNAs regulate cellular activities at the nuclear level, others are local-
ized within the cytosol and mediate post-transcriptional control via
RNA–RNA interactions (Chapman et al., 2014). They can act as sponges
and interact with short non-coding RNAs, such as miRNAs to simulta-
neously inﬂuence the expression of several thousands of miRNA-
target genes leading to an overall change in cellular physiology.
The functional heterogeneity of lncRNAs is further emphasized by
their ability to contribute to multi-protein complex formation and
participate in protein localization and function. In addition, a role for
lncRNA as mediators of intercellular signaling is also being recognized
by studies that have demonstrated the presence of lncRNA within
extracellular vesicles, their release during conditions of cellular stress,
and their ability to modulate cellular responses in recipient cells after
uptake of these vesicles (Kogure, Yan, Lin, & Patel, 2013; K. Takahashi,
I.K. Yan, H. Haga et al., 2014; K. Takahashi, I.K. Yan, K.Wood et al., 2014).
2. LncRNA in human cancers
The ability of lncRNA to alter cellular physiology by altering gene ex-
pression raises the possibility that deregulated lncRNA expression may
contribute to disease pathophysiology. Altered expression of lncRNA
has been reported in many cancers and in other disease settings.
Based on the emerging literature, lncRNA may be useful in elucidating
Table 1
Long non-coding RNA-mediated regulatory mechanisms.
lncRNA Function Mechanism Reference
mRNA transcription
HOTAIR ↓ at the HOXD locus Chromatin-mediated ↓ (Tsai et al., 2010)
HOTTIP ↑ at the HOXA locus Chromatin-mediated ↑ (K. C. Wang et al., 2011)
XIST X inactivation Chromatin-mediated ↓ (Zhao, Sun, Erwin, Song, & Lee, 2008)
ANRIL ↓ at the INK4b-ARF-INK4a locus Chromatin-mediated ↓ (Kotake et al., 2011)
KCNQ1OT1 Imprinting at the KCNQ1 cluster Chromatin-mediated ↓ (Pandey et al., 2008)
GAS5 ↓ of glucocorticoid receptor- mediated
transcription
DNA mimicry (Kino, Hurt, Ichijo, Nader, & Chrousos, 2010)
CCND1 promoter RNA ↓ of CCND1 transcription Allosteric ↑ of TLS (X. Wang et al., 2008)
NRON ↓ of NFAT-mediated transcription ↓ of transcription factor nucleocytoplasmic
shuttling
(Willingham et al., 2005)
AIRN Imprinting at the IGF2R cluster Chromatin-mediated ↓, transcription
interference
(Latos et al., 2012)
IME4 antisense ↓ of IME4mRNA Transcription interference (Hongay, Grisaﬁ, Galitski, & Fink, 2006)
SRG1 ↓ of SER3mRNA Nucleosome remodeling (Hainer, Pruneski, Mitchell, Monteverde,
& Martens, 2011)
ICR1 and PWR1 ↓ and ↑ of FLO11mRNA, respectively Modulation of transcription factor
recruitment
(Bumgarner et al., 2012)
Alu repeat-containing RNA Transcriptional ↓ during heat shock ↓ of Pol II (Mariner et al., 2008)
HSR1 ↑ of HSF1 Allosteric ↑ together with eEF1A (Shamovsky, Ivannikov, Kandel, Gershon, &
Nudler, 2006)
mRNA processing
MALAT-1 Serine/Arginine splice factor modulation Scaffolding nuclear domain (Tripathi et al., 2010)
ZEB2 ↑ of ZEB2 translation Controlled splicing of IRES-containing
intron region
(Beltran et al., 2008)
NeuroblastomaMYC ↓ of neuroblastoma MYC intron 1 splicing Controlled splicing via RNA–RNA duplex
formation
(Krystal, Armstrong, & Battey, 1990)
Sas10mRNA 3′ UTR ↓ of Rnp4FmRNA RNA editing (Peters, Rohrbach, Zalewski, Byrkett, &
Vaughn, 2003)
Post-transcriptional modulation
HULC ↓ of miRNA-mediate repression Sequestration of miRNAs (J. Wang et al., 2010)
PTENP1 pseudogene ↑ of PTEN Sequestration of miRNAs (Poliseno et al., 2010)
CDR1as ↓ of miRNA-mediate repression Sequestration of miRNAs (Hansen et al., 2013)
BACE1AS ↑ of BACE1 Blocking miRNA-induced repression (Faghihi et al., 2010)
Antisense UCHL1 ↑ of UCHL1 protein level Translational upregulation (Carrieri et al., 2012)
Protein activity
EVF2 Transcriptional ↑ of DLX2 targets ↑ of DLX2 (Feng et al., 2006)
15q11-q13 sno-lncRNA Alternative splicing ↓ of FOX2 function (Yin et al., 2012)
mcs-1 Dicer-mediated ↓ Sequestration of Dicer or other RNA-binding
proteins
(Hellwig & Bass, 2008)
sfRNA Stabilization of viral and host mRNAs ↓ of XRN1- mediated mRNA degradation (Moon et al., 2012)
gadd7 ↓ of TDP43-mediated regulatory events Sequestration of TDP43 (X. Liu, Li, Zhang, Guo, & Zhan, 2012)
Protein complex organization
HOTAIR ↓ at the HOXD locus Recruitment of PRC2 and LSD1 (Tsai et al., 2010)
KCNQ1OT1 Imprinting at the KCNQ1 cluster Recruitment of PRC2 and G9A (Pandey et al., 2008)
ANRIL ↓ at the INK4b-ARF-INK4a locus Recruitment of PRC1 and PRC2 (Kotake et al., 2011; Yap et al., 2010)
TERC Inclusion of telomeric repeats to
chromosomal ends
Scaffolding for telomere components and
template identiﬁcation for repeat sequences
(Zappulla & Cech, 2004)
NEAT1 Paraspeckles formation Nucleation of subnuclear domains (Sasaki, Ideue, Sano, Mituyama, &
Hirose, 2009)
SRP RNA Guiding proteins to ER Scaffolding of SRP components (Halic et al., 2004)
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ations in lncRNA are associated with disease states, lncRNA may have
roles as therapeutic targets or as biomarkers of disease (Table 2). Recent
studies implicate the potential role of lncRNAs in cancer development
by virtue of their ability to interact with DNA, RNA, proteins, and/or
their combinations, and their potential to modulate many of the hall-
marks of cancer (Fig. 3). A speciﬁc group characterized by non-coding
repeats can activate immune responses and contribute to disease pro-
gression (Chiappinelli et al., 2015; Leonova et al., 2013; Rooney,
Shukla, Wu, Getz, & Hacohen, 2015; Roulois et al., 2015; Tanne et al.,
2015). Examples include LINE-1.HERV, Satellites, and TERRA. In addition,
the LINE-1 repeat (CoT-1) may affect chromatin formation. These re-
peats are actively reverse transcribed and re-incorporate in the genome
in cancers, thus causing an expansion of speciﬁc genomic regions
(Bersani et al., 2015; Hall et al., 2014; Iskow et al., 2010; E. Lee et al.,
2012; Rodic et al., 2015). TERRA plays a role in telomere extensionthrough the alternative lengthening of telomeres (ALT) pathway
(Flynn et al., 2011).
The emergence of comprehensive detection technology such as
RNA-seq has enabled the cataloging of databases with information on
several lncRNAs that are deregulated or aberrantly expressed in several
types of cancers such as hepatocellular carcinoma (HCC), gastric cancer,
renal cancer, colorectal cancer, glioma, prostate cancer, and others.
High-throughput, comprehensive and multi-dimensional data analyses
have extended our knowledge about molecular regulatory mechanisms
of lncRNAs that can control speciﬁc tumor-related behavior, thus adding
a new stratum of key mediators and regulatory complexity during the
evolution of cancer.
To highlight these, we will use liver cancers as an illustrative exam-
ple. Liver cancers such asHCC are ideal to study lncRNA targets for treat-
ment because liver uptake and delivery may be feasible for some
therapeutic approaches. Several lncRNAs have been identiﬁed to play
Fig. 2. lncRNA interactions and actions. (A) LncRNAs can target genomic DNA loci and can modulate gene transcription by associating with RNA pol II or pre-initiation complexes, or
through epigenetic modulation by guiding chromatin-modifying complexes to target genomic DNA loci. (B) LncRNA can contribute to RNA inhibition or degradation, by association
with mRNAs and miRNAs to regulate splicing, or by acting as endogenous sponges. (C) LncRNAs can modulate protein activity and localization by acting as molecular guides and
scaffolds or as decoys for proteins such as transcription factors.
Table 2
Long non-coding RNA associated with human diseases.
Disease Type of disease lncRNA Reference
Cardiovascular
disease
Myocardial infarction MIAT (Ishii et al., 2006)
Myocardial ischemia HIF1A (Zolk, Solbach, Eschenhagen, Weidemann, & Fromm,
2008)
Diabetes Transient neonatal diabetes mellitus HYMAI (Mackay et al., 2002)
PINK1-AS (Scheele, C., Nielsen, A. R., et al., 2007)
Genetic disorders X-fragile syndrome FMR4 (Khalil, Faghihi, Modarresi, Brothers, & Wahlestedt,
2008)
HELLP Syndrome HELLPAR (van Dijk et al., 2012)
Silver-Russell, Beckwith-Wiedemann
syndrome
KCNQ1OT1 (Chiesa et al., 2012)
Duchenne muscular dystrophy Linc-MD1 (Cesana et al., 2011)
Facioscapulohu-meral muscular
dystrophy
DBET (Cabianca et al., 2012)
Neurological
disorders
Alzheimer's disease BACE1-AS, NAT-Rad18, 17 A (Faghihi et al., 2008)
Schizophrenia DISC2, GOMAFU (Chubb, Bradshaw, Soares, Porteous, & Millar, 2008)
Huntington TUNA (N. Lin et al., 2014)
Parkinson naPINK1 (Scheele, C., Petrovic, N., et al., 2007)
Cancer Female cancers (breast, ovary,
uterine, cervical)
HOTAIR, H19, GAS5, ANRASSF1, UCA1,
SRA, PVT1, CCAT2,MALAT-1, XIST
(L. Cui, X.Y. Xie et al., 2013; Khalil et al., 2008; Kino
et al., 2010; Mizrahi et al., 2009; Z. Zhang et al., 2014)
Colon MALAT-1/NEAT2, PTENP1, HOTAIR, CCAT1,
CCAT2, CRNDE, CUDR, H19, PVT1, KCNQ1OT1,
ncRAN/SNHG16
(L. D. Graham et al., 2011; M. Z. Ma et al., 2015;
Michalik et al., 2014; Nakano et al., 2006)
Renal CUDR, H19, UCA1, ncRAN/SNHG16, (Fan et al., 2014; Y. Wang et al., 2012)
Liver HULC, HOTAIR, TUC338, H19,MEG3, lncRNA-ATB,
HEIH, PCNA-AS1,MALAT-1, HOTTIP, linc-RoR
(Anwar et al., 2012; Du et al., 2012; Geng, Xie, Li,
Ma, & Wang, 2011; Ishibashi et al., 2013; K. Takahashi,
I.K. Yan, T. Kogure, et al., 2014; Yuan et al., 2014)
Prostate PCA3, ANRIL/p15AS,MALAT-1/NEAT2, PCAT-1,
PCGEM1, PTENP1, CTBP1-AS, ANRASSF1, NEAT1,
PlncRNA-1, PRNCR1, SRA,SChLAP1/PCAT114
(Chung et al., 2011; Z. Cui, S. Ren et al., 2013;
Kotake et al., 2011; G. L. Lee, Dobi, & Srivastava, 2011;
Petrovics et al., 2004; Prensner et al., 2011)
Lung MALAT-1/NEAT2, linc-p21, TUG1, CCAT2, CUDR,
HOTAIR, PVT1, AK126698
(Dingemans et al., 2014; Gutschner et al., 2013; Hou
et al., 2014; Qiu et al., 2014; Y. Yang, H. Li et al., 2013)
Leukemia ANRIL/p15AS, uc.73a,MEG3, HOTTIP, XIST, PVT1, NEAT1 (Folkersen et al., 2009; M. Graham & Adams, 1986;
Rack et al., 1994; Zeng et al., 2014)
Gastrointestinal CCAT1, H19, HOTAIR, PVT1,MALAT-1 (Ding et al., 2014; Fellig et al., 2005; J. H. Liu, Chen,
Dang, Li, & Luo, 2014; C. Ma et al., 2014)
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Fig. 3. lncRNAs associated with hallmarks of cancer. LncRNAs have been implicated in key hallmarks of cancer and can contribute to the onset and progression of cancer.
71M.A. Parasramka et al. / Pharmacology & Therapeutics 161 (2016) 67–78a functional role in HCC initiation and progression, as well as associated
with recurrence,metastases, or prognosis. These RNA genes could regu-
late epigenetic events in conjunction with chromatin-modifying factors
such as chromatin, histone-modifying enzymes, and DNA-methylatingTable 3
Functional role of long noncoding RNAs in hepatocellular carcinoma.
lncRNA Classiﬁcation Genome location Effects
HULC LincRNA Chr6 Promotes proliferation, p
histological grade or HBV
HOTAIR Antisense Chr12 Promotes metastasis, neg
chemosensitivity and po
invasion and recurrence
HOTTIP Bidirectional Chr7 Promotes proliferation, p
outcome and tumor prog
HEIH LincRNA Chr5 Promotes proliferation b
associated with HBV-HCC
H19 LincRNA Chr11 Increased in HCC, suppre
miR-220 dependent path
drug resistance
LALR1 Antisense Chr17 Promotes proliferation
LET Intronic Chr15 Suppresses metastasis
MALAT-1 LincRNA Chr11 Promotes metastasis and
invasion, and synaptogen
MEG3 LincRNA Chr14 Induces apoptosis, epigen
with methylation
MVIH Sense Chr10 Promotes angiogenesis, i
recurrence-free survival
RERT Sense Chr19 Not understood
uc002mbe.2 LincRNA Chr19 Induce apoptosis
Linc-ROR LincRNA Chr18 Tumor cell survival durin
Dreh Sense Chr17 Promotes metastasis
PCNA-AS1 Antisense Regulates proliferation a
UCA1/CUDR Intronic Chr19 Chemotherapeutic resist
PVT1 Variant Chr8 Regulates proliferation, c
properties
TUC338 Ultra-conserved Chr12 Enhanced levels in liver c
regulates cell growthagents leading to altered expression of target genes. The downstream
cellular functions of these lncRNA transcripts are better understood
than the mechanisms by which the expressions of these lncRNAs are
regulated, or their relevance to genetic or somatic mutations relatedReference
ositive correlation with (Du et al., 2012; J. Wang et al., 2010; Xie, Ma, &
Zhou, 2013)
ative association with
sitively associated with
(Geng et al., 2011; Ishibashi et al., 2013; Z. Yang, L.
Zhou et al., 2011)
redictor of disease
ression
(Quagliata et al., 2014)
y modulating cell cycle, (F. Yang, L. Zhang et al., 2011)
sses metastasis via
way and associated with
(Iizuka et al., 2002; Tsang & Kwok, 2007; L. Zhang
et al., 2013)
(Xu et al., 2013)
(F. Yang, X.S. Hou et al., 2013)
recurrence, migration,
esis
(Lai et al., 2012; R. Lin, Maeda, Liu, Karin, &
Edgington, 2007)
etic modulator associated (Anwar et al., 2012; C. Braconi, T. Kogure, et al.,
2011)
mportant predictor of (Yuan et al., 2012)
(Zhu et al., 2012)
(L. Zhang et al., 2013)
g hypoxia (K. Takahashi, I.K. Yan, H. Haga, et al., 2014)
(J. F. Huang et al., 2013)
nd cell cycle (Yuan et al., 2014)
ance (Tsang, Wong, Cheung, Co, & Kwok, 2007)
ell cycle, and stem cell-like (F. Wang, J.H. Yuan et al., 2014)
irrhosis and HCC, (C. Braconi, N. Valeri, et al., 2011)
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are associated with HCC are listed in Table 3. We emphasize that
these may represent just the tip of the iceberg, as many other lncRNA
related to HCC or other cancers remain to be identiﬁed. To illustrate
the diversity of functional mechanisms, we discuss a few of these
herein (Fig. 4).
A classic example of lncRNA gene networking in HCC is Highly up-
regulated lncRNA in liver cancer (HULC). Overexpression of HULC is as-
sociated with low-stage and low-grade tumors, implying a functional
role in early stage of cancer progression. The cAMP response element-
binding protein (CREB) binds to a binding site in the promoter region
of HULC, and this association leads to an autoregulatory loop of HULC
with miR-372 via its conserved target site causing inhibition of transla-
tional repression of the catalytic subunit of PKA (PRKACB), a miR-372
target. This in turn increases the phosphorylation of CREB, making it
more available to bind to proximal promoter of HULC. Overall,
this autoregulatory loop leads to increased expression of HULC in HCC
(J. Wang et al., 2010). HULC can also promote proliferation of HCC by
targeting and suppressing p18. IGF2BP1, an oncofetal protein acts in
trans to regulate HULC stability and expression by acting as a guide by
bringing HULC into close proximity to the CCR4-NOT1 deadenylase
complex (Hammerle et al., 2013). Metastasis associated in lungFig. 4. Examples of mechanisms of lncRNAs associated with liver cancers. (A) Epigenetic silencin
gene locus and regulate the expression of its target genes. (B) Splicing modulation:MALAT-1 tra
factors to generate spliced variants. (C) lncRNA-miRNA interactions: lncRNA HULC acts as a m
phosphorylation and activation of CREB (cAMP response element-binding protein), thus
interactions: lncRNA HULC binds to oncofetal protein IGF2BP1 and guides it to its associating paadenocarcinoma transcript 1 (MALAT-1) is another lncRNA that is up-
regulated in HCC; Although the mechanistic contribution of MALAT-1
to HCC is not known, MALAT-1 is associated with alternative splicing
and interacts with SF2/ASF and CC3 antigen to modulate SR proteins
(serine/arginine-rich family of nuclear phosphoproteins) that regulate
splicing of various pre-mRNAs (Lai et al., 2012; R. Lin et al., 2007).
LncRNAhigh expression inHCC (HEIH) can contribute to cell cycle arrest
by associationwith enhancer of zeste homolog 2, a part of polycomb re-
pressive complex 2 that leads to its recruitment to p16 promoter region,
thereby preventing the expression of p16 gene (J. J. Huang et al., 2015; F.
Yang, L. Zhang et al., 2011). Non-coding repeat LINE-1 insertions occur
with high frequency in HCC (Shukla et al., 2013) LncRNAs can also
bind withmiRNAs as sponges to regulate gene expression. These exam-
ples serve to illustrate the diversity of many unique lncRNA-based
mechanisms in HCC.
The detection of certain lncRNAs in body ﬂuids, like urine and plas-
ma, makes them potential biomarkers of disease, similar to circulating
miRNA. To explore the potential role of lncRNA as biomarkers, it will
be necessary to establish the expression and stability of circulating
lncRNAs in healthy and diseased states. For example, plasma levels of
lncRNA HULC are higher in patients with HCC patients than in healthy
controls. Similarly, PCA3, a prostate-speciﬁc lncRNA that is signiﬁcantlyg: lncRNA HEIH binds to EZH2 subunit of PRC2 complex, directing this complex to speciﬁc
nscript within the nuclear speckles modulates the activity of serine/arginine (SR) splicing
olecular sponge to sequester miRNA-372 and de-repress PRKACB expression to enable
stimulating HULC expression to activate an autoregulatory loop. (D) lncRNA-protein
rtner CCR4-NOT1 complex.
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diagnostic biomarker for prostate cancer (G. L. Lee et al., 2011).
Establishing the relationship between circulating lncRNA and the
disease course may yield prognostic markers, as suggested by a report
of ncRNA MALAT-1, as an early prognostic indicator of poor survival
rate in HCC.
Although the correlation between lncRNAs and human cancers is
recognized, detailed mechanistic information regarding the contribu-
tion of lncRNA to these cancers is currently lacking. Nevertheless, the
rapidly growing interest and emerging data are likely to provide many
new mechanistic insights into the contributions of lncRNA in cancer,
and thereby are expected to identify novel candidates for therapeutic
intervention or biomarkers.
3. Therapeutic approaches to targeting lncRNA in cancers
Differential expression of lncRNA in tumors compared with normal
tissues has been reported for many different cancers. The identiﬁcation
of lncRNA that are involved in cellular processes contributing to onco-
genesis, tumor suppression, or tumorigenesis provides opportunities
to develop novel therapeutics for cancer that are based on targeting
lncRNA (Kimura et al., 2015; Sasaki et al., 2009). These genes differ
from protein-coding RNA or miRNA in several ways that need to be
considered in analyzing their effects or in exploring their therapeutic
potential. First, their structural complexity and participation in multi-
component complexes provides several potential targetable critical
residues to modulate structure-based interactions. Second, they can
subserve key regulatory roles in gene expression at absolute expression
levels that are low in comparisonwith protein-coding genes. Third, they
demonstrate tissue or cell-type speciﬁcity in expression. In addition,
their effects can result from very diverse mechanisms of action, and
they may also participate in intercellular communication. Finally, our
current understanding of RNA gene function emphasizes the combina-
torial nature of their action, which can result in complex interactions
that incorporate multiple associated effectors. As a consequence, the
functional impact of targeting lncRNAneeds to be analyzed in a system-
ic context rather than as an individual target (See Table 4.).
Several different types of approaches can be considered to target
lncRNA and to modulate their expression for therapeutic purposes
(Fig. 5).
3.1. Silencing of lncRNAs
Similar to other genes, lncRNA can be targeted by using speciﬁc
small interfering RNAs (siRNAs) that associate with RISC (RNA-induced
silencing complex) complex and bind to speciﬁc target sequence based
on complementarity leading to argonaute-mediated degradation of
target sequence. For example, in a study by Hung et al., siRNA againstTable 4
LncRNA-based therapeutic approach in cancer.
Agent Description and mechanism
Small interfering RNAs (siRNAs) Double-stranded RNAs that associate with RISC c
degradation depending on perfect sequence com
Antisense oligonucleotides (ASOs)
Example: LNA Gapmers
Single-stranded oligonucleotide sequence (13–25
complementarity for
target lncRNA. Effective binding with secondary s
degradation or blocking of the translational appa
Ribozymes and deoxyribozymes
(Hammerhead ribozymes)
A RNA (ribozyme) or DNA (deoxyribozyme) mol
to cleave RNA in a site-speciﬁc manner. ~20 nucl
loop target=speciﬁc lncRNAs for cleavage
Aptamer Single-stranded RNA or DNA oligonucleotides cap
peptides, proteins, RNA, lncRNA, and live cells by
3-dimensional shapes
Small-molecule drugs Chemical compounds that block the activity of ta
to regulate activitypromoter of CDKN1A antisense DNA damage activated RNA (PANDA)
signiﬁcantly reduced its expression and sensitized human ﬁbroblasts
to doxorubicin-induced apoptosis (Kimura et al., 2015; Regha, Latos, &
Spahn, 2006; F. Wang, J.H. Yuan et al., 2014).
3.2. Natural antisense transcripts
Natural antisense transcripts (NATs) are a type of lncRNA and their
use illustrates an example of extending knowledge of lncRNA to design
effective therapeutics. Inhibition of NATs can increase sense mRNA
transcript levels (Modarresi et al., 2012) and the use of AntagoNATs is
being evaluated as a therapeutic approach to upregulate the expression
of speciﬁc sense mRNA (H. Takahashi & Carninci, 2014).
3.3. Antisense oligonucleotide
Therapeutic strategies based on antisense oligonucleotide (ASO)
could be used to target the expression and function of speciﬁc lncRNAs.
ASOs are single-stranded oligonucleotides that offer speciﬁc comple-
mentarity and RNase H-mediated degradation of target sequence. The
feasibility of ASO-mediated knockdown to modulateMALAT-1 function
has been demonstrated in lung cancer cells and murine xenografts
where metastasis was restricted. ASO may be more effective than
siRNAs for lncRNA targets in which the secondary structure of the
lncRNA might preclude or limit optimal association with a siRNA.
However, as with other ASO-targeting strategies, the adequacy of
cellular uptake and potential for off-target effects needs to be consid-
ered (Gutschner et al., 2013; Kotake et al., 2011; Lebo, Niederer, &
Zappulla, 2015; Zappulla & Cech, 2006).
3.4. Locked nucleic acid GapmeRs
The use of these provides an alternative to RNAi-knockdown of
upregulated lncRNAs. These single-stranded oligonucleotide consist of
a DNA stretch ﬂanked by locked nucleic acid (LNA) nucleotides and,
similar to ASOs, form base pairs with target lncRNA to induce degrada-
tion via RNAse H-dependent mechanism (Yang, Lu, & Yuan, 2014).
Inhibition ofMALAT-1 using GapmeRs resulted in a functional reduction
in blood ﬂow recovery and capillary density after hind limb ischemia
(Michalik et al., 2014). However, this approach is currently limited
only to nuclear localized oncogenic lncRNAs.
3.5. Ribozymes or deoxyribozmes
Catalytic degradation is another therapeutic strategy. These
enzymes can target RNA and cleave in a site-speciﬁc manner via a
protein-independent mechanism. ‘Hammerhead’-ribozymes are de-
signed to have ~20 nt long arms ﬂanking a central loop and theseProgress made
omplex and exhibit argonaute-mediated
plementarity
Preclinical studies
nucleotides long) with perfect
tructure of lncRNAs, RNase-H-mediated
ratus
Preclinical studies, Phase I and IIa
ecule that exhibits catalytic properties
eotide long “arms” ﬂanking a central
Preclinical studies
able of efﬁciently targeting small molecules,
virtue of transforming to well-deﬁned
Preclinical studies and early stage
clinical trials
rget lncRNAs by structure-speciﬁc docking Preclinical studies
Fig. 5. Strategies to target lncRNA. (A) Gene transcription: DNA-binding elements can target the genomic locus to alter lncRNA transcription. (B) Transcript destabilization/degradation:
siRNAs (19–30 nt long double-stranded RNAs) can bind to complementary lncRNA sequences through RISC (RNA-induced silencing complex). ASO and Gapmers (8–50 nt long single-
stranded DNAs or RNAs can carry out sequence speciﬁc and RNase H-mediated lncRNA degradation. Ribozymes (single-stranded RNA in neutral condition) can undergo cellular
processing to expose the hammerhead structure of the binding arms that bind with target sites and result in cleavage of the target lncRNA. (C) Block interactions. Small synthetic
molecules can block binding of lncRNAs with protein, DNA, RNA or other interacting complexes by associating with speciﬁc binding pockets. (D) Functional disruption:
Aptamers (3- dimensional short RNA or DNA oligonucleotides) can bind at speciﬁc structural regions to target lncRNA and antagonize their association with their binding partners.
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liver metastasis was observed by anti-VEGFR-1/2 ribozymes in preclini-
cal studies in colon cancer model (Pavco et al., 2000). However,
secondary structures of lncRNAs often disrupt efﬁcient binding of
these molecules to speciﬁc targets.
3.6. Aptamers
The use of single-stranded oligonucleotide or peptide aptamers
could overcome limitations imposed by structural features as they
could bind by forming tertiary structures with their targets. Thus, they
may provide a greater speciﬁcity than siRNAs, ASOs, or ribozymes.
Moreover, the chemical structure of aptamers could be modiﬁed to en-
hance their stability and half-life. Aptamer-based therapeutics are
promising and undergoing clinical trials for many different indications
such as non-small-cell lung cancer, renal cell carcinoma, and acute
myeloid leukemia (Vitiello, Tuccoli, & Poliseno, 2015). In 2004, an
anti-VEGF aptamer (Eyetech Pharmaceutics/Pﬁzer) was approved by
FDA for macular degeneration.
3.7. Small-molecule inhibitors
As discussed above, lncRNAs exhibit dynamic binding afﬁnities to
various cellular components. Small molecules can mask the binding
site for lncRNAs and prevent the association with its binding partners
or antagonistic oligonucleotide sequences to disrupt interactions that
are linked to altered function in disease-related lncRNA. For example,
a small-molecule inhibitor that prevents the binding of an oncogenic
lncRNA, HOTAIRwith its binding partners could restrict tumor cell inva-
sion, angiogenesis, and metastatic potential (Tsai, Spitale, & Chang,
2011). Small molecules and oligonucleotides can also be used tointerfere with the formation of RNA structures and disrupt folding pat-
terns that modulate function.
3.8. RNA destabilizing elements
These can regulate lncRNA expression at the genomic level, and con-
fer a knockout-like effect on gene function. RNA destabilizing elements
(RDEs) have been successfully employed to reduceMALAT-1 expression
(Miller et al., 2007).
3.9. Synthetic lncRNA mimics and other constructs
The use of synthetic mimics are being developed and tested for their
ability to act as a decoy to block transcription of target genes or to re-
store their function. Alternatively, a plasmid BC-819 (DTA-H19) has
been designed to speciﬁcallymediate its action throughhigh abundance
lncRNA H19 promoter to induce high levels of diphtheria toxin in
tumors. The use of this construct has been shown to lead to an overall
reduction in tumor size in human trials in several carcinomas although
the underlying mechanisms need to be investigated (Mizrahi et al.,
2009).
Several approaches to target lncRNA for therapeutic purposes can be
considered once critical disease-relevant contributions of these genes
have been identiﬁed. A major challenge of all of these approaches is to
accomplish target-speciﬁc delivery. The use of synthetic nanoparticles
for delivery of biologically active constructs has been extensively
investigated. An alternative approach involves the use of extracellular
vesicles, biologically derived particles that are involved in intercellular
communication, and could be packaged with RNA genes for successful
targeted therapy (Hongay et al., 2006; Kimura et al., 2015). We have re-
cently shown that lncRNAswithin extracellular vesicles retain function-
al activity after they are taken up by recipient cells (K. Takahashi, I.K.
Fig. 6. LncRNA-mediated mechanisms of therapeutic resistance. Mechanisms of tumor cell resistance to chemotherapy or hypoxia involving lncRNA include modulation of drug
transporters and elimination, survival signaling pathways, cell cycle progression and DNA repair, sensitization to apoptosis, and modulation of intercellular communication mediated
by extracellular vesicles.
75M.A. Parasramka et al. / Pharmacology & Therapeutics 161 (2016) 67–78Yan, T. Kogure et al., 2014). The use of extracellular vesicles as delivery
vehicles for lncRNA is thus highly attractive. Effective, target-speciﬁc
therapy can be designed by fusing exosome membrane protein with
speciﬁc peptides. Other potential advantages may include immune
tolerance with the use of autologous vesicles, ability to traverse the
blood–brain barrier, and more effective tissue penetration into target
tissues such as tumors.
Therapeutic resistance is a major challenge that limits the efﬁcacy of
cancer treatments. The role of lncRNAs in conferring differential drug-
resistance phenotype is becoming appreciated, and severalmechanisms
for therapeutic resistance are now recognized. These include involve-
ment of lncRNA in modulating survival signaling pathways, drug trans-
porter expression and elimination, sensitization to apoptosis, DNA
repair and cell cycle progression, and intercellular communication me-
diated by extracellular vesicles (Fig. 6). A proposedmechanism involves
trans-regulatory modulation of P-glycoprotein (P-gp) that regulates
drug elimination in resistant cells. P-gp is in turn regulated by multi-
drug resistance-related and upregulated lncRNA (MRUL)with inhibition
ofMRUL leading to increased chemotherapeutic drug-mediated apopto-
sis via reduction of P-gp expression and followed by impaired chemo-
therapeutic expulsion (Thiebaut et al., 1987; Y. Wang, D. Zhang et al.,
2014). Some lncRNAs have the ability to re-sensitize chemoresistant
cancer cells to therapeutic agents like cisplatin by modulating DNA
damage response pathways. Cisplatin-mediated upregulation ofHOTAIR
in human lung adenocarcinoma cells suppressed p21 (WAF1/CIP1)
signaling pathway and caused a G0/G1 arrest by modulating the p53
expression (Z. Liu et al., 2013). Another lncRNA, urothelial cancer-
associated 1 (UCA1) increased cisplatin-mediated resistance in human
bladder cancer cells by regulating the Wnt signaling pathway. A
proposed mechanism is upregulation of wingless-type MMTV integra-
tion site family member 6 (Wnt6), making this a potential target to
overcome chemoresistance (Fan et al., 2014). Similarly, lncRNA
AK126698modulated cisplatin resistance in non-small-cell lung cancer
cells via Wnt pathway (Hou et al., 2014; Y. Yang, H. Li et al., 2013). We
identiﬁed a novel lncRNA, lincRNA-ROR to be involved in mediating
chemoresistance in human hepatocellular cells. Interestingly, this
lncRNA was highly enriched within extracellular vesicles derived from
HCC tumor cells and caused an increased lincRNA-ROR expression andreduced chemotherapy-induced cell death in recipient cells by modu-
lating levels of TGFβ (tumor growth factor-beta) (K. Takahashi, I.K.
Yan, T. Kogure et al., 2014). LncRNA GAS5 renders glucocorticoid
resistance by assuming a secondary structure that competes with the
sequence within the response gene promoter region (Kino et al.,
2010). PANDA contributes to anthracycline resistance in a subset of
breast cancer cells by coordinating with NF-YA, a nuclear transcription
factor that regulates apoptosis. Down-regulation of PANDA led to in-
creased chemotherapy sensitivity thus, suggesting a crucial role in
drug resistance (Malek, Jagannathan, & Driscoll, 2014).
Although in vitro studies may provide promising results with
regards to lncRNA function and their use as therapeutic targets,
in vivo validation is extremely challenging and requires optimization
at various levels. The poor conservation of lncRNA across species can
confound the interpretation of data from animal studies. Our under-
standing of themechanisms of action is rudimentary, andmany intrigu-
ing questions remain unanswered such as the recruitment criteria for
chromatin-remodeling complexes, whether or not the binding partners
of lncRNAs are constant, or the impact of environment, localization, or
associated disease states on lncRNA expression and function. The ad-
vent of genome engineering capabilities such as TALEN or CRISPR/Cas9
methodologies will enable the detailed study of lncRNA function
(Hainer, Charsar, Cohen, & Martens, 2012; Hongay et al., 2006). Deﬁni-
tion of the repertoire of lncRNA in normal tissues or cells and in disease
conditionswill be necessary. There is a need to develop adequately sen-
sitive detection techniques, and to comprehensively deﬁne structural
and functional motifs and modules. Even with established targets for
intervention, careful in vivo analyses will be necessary, followed by val-
idation in appropriate patient cohorts. As the pace of research in
lncRNAs progresses, addressing these challenges and gaps will provide
opportunities for the development of novel therapeutic strategies
based on targeting lncRNA for human cancers and other diseases.
4. Conclusions
Our current knowledge regarding lncRNAprovides the basis and jus-
tiﬁcation to further develop applications of lncRNA as disease markers
and therapeutic targets. As discussed above, lncRNAs can interact with
76 M.A. Parasramka et al. / Pharmacology & Therapeutics 161 (2016) 67–78DNA, mRNA, ncRNAs and proteins to alter cellular physiology, can be
deregulated in diseases such as cancer, and can form the basis for ther-
apeutic intervention. Although a holistic and integrated approach that
incorporates lncRNA with other proteins and genes will be necessary
to successfully develop effective therapies, adding these RNA genes to
our future armamentarium of therapeutics is likely to be very beneﬁcial
by providing new opportunities for intervention.
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